Cargando…

Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain

Chronic myeloid leukemia (CML) is caused by the kinase activity of the BCR-Abl fusion protein. The Abl inhibitors imatinib, nilotinib and dasatinib are currently used to treat CML, but resistance to these inhibitors is a significant clinical problem. The kinase inhibitor bosutinib has shown efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Levinson, Nicholas M., Boxer, Steven G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320885/ https://www.ncbi.nlm.nih.gov/pubmed/22493660 http://dx.doi.org/10.1371/journal.pone.0029828

Ejemplares similares

Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
por: Rassi, Fuad El, et al.
Publicado: (2013)

A conserved water-mediated hydrogen bond network defines bosutinib’s kinase selectivity
por: Levinson, Nicholas M., et al.
Publicado: (2013)

Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling
por: Bieerkehazhi, Shayahati, et al.
Publicado: (2016)

Bosutinib: A Novel Src/Abl Kinase Inhibitor for Chronic Myelogenous Leukemia
por: Steinbach, Alison, et al.
Publicado: (2013)

Bosutinib-Induced Stevens-Johnson Syndrome and Evidence of Tolerance to a Structurally Dissimilar Tyrosine Kinase Inhibitor
por: Avila-Castano, Karol, et al.
Publicado: (2022)

Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity
por: Moguillansky, Natalia I., et al.
Publicado: (2017)

Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) Study
por: Isfort, Susanne, et al.
Publicado: (2023)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth
por: Tauer, Josephine Tabea, et al.
Publicado: (2013)

Bosutinib for Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2015)

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2015)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Pregnancy outcomes in patients treated with bosutinib
por: Cortes, Jorge E, et al.
Publicado: (2020)

Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study
por: Yuda, Junichiro, et al.
Publicado: (2022)

Incident pulmonary arterial hypertension associated with Bosutinib
por: Yo, Shaun, et al.
Publicado: (2020)

A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors
por: Karim, Nagla Abdel, et al.
Publicado: (2022)

Correlation of plasma concentration and adverse effects of bosutinib: standard dose or dose-escalation regimens of bosutinib treatment for patients with chronic myeloid leukemia
por: Mita, Akiko, et al.
Publicado: (2018)

Protective effect of Bosutinib with caspase inhibitors on human K562 cells
por: Baty, Roua S.
Publicado: (2022)

The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases
por: Ozanne, James, et al.
Publicado: (2015)

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
por: Hochhaus, Andreas, et al.
Publicado: (2023)

Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study
por: Cortes, Jorge E., et al.
Publicado: (2023)

Control of mammary tumor differentiation by SKI-606 (bosutinib)
por: Hebbard, Lionel, et al.
Publicado: (2010)

Bosutinib in chronic myeloid leukemia: patient selection and perspectives
por: Isfort, Susanne, et al.
Publicado: (2018)

Bosutinib Inhibits EGFR Activation in Head and Neck Cancer
por: Segrelles, Carmen, et al.
Publicado: (2018)

Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy
por: Abumiya, Maiko, et al.
Publicado: (2021)

Molecular dynamics simulations of the conformational plasticity in the active pocket of salt-inducible kinase 2 (SIK2) multi-state binding with bosutinib
por: Shi, Mingsong, et al.
Publicado: (2022)

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib
por: Redaelli, Sara, et al.
Publicado: (2015)

Synthesis of Bosutinib from 3-Methoxy-4-hydroxybenzoic Acid
por: Yin, Xiao Jia, et al.
Publicado: (2010)

Bosutinib Therapy Ameliorates Lung Inflammation and Fibrosis in Experimental Silicosis
por: Carneiro, Priscila J., et al.
Publicado: (2017)

Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies
por: Pagan, Fernando L., et al.
Publicado: (2022)

A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
por: Levinson, Nicholas M, et al.
Publicado: (2006)

Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations
por: Sweet, Kendra, et al.
Publicado: (2014)

Inhibition of Soluble Epoxide Hydrolase Attenuates Bosutinib-Induced Blood Pressure Elevation
por: Cui, Zhen, et al.
Publicado: (2021)

Bosutinib-induced lung injury: a report of two cases and literature review
por: Watanabe, Naoki, et al.
Publicado: (2022)

Rapid LC-MS/MS Bosutinib Quantification with Applications in Metabolic Stability Estimation
por: Attwa, Mohamed W., et al.
Publicado: (2023)

Bosutinib high density lipoprotein nanoformulation has potent tumour radiosensitisation effects
por: Dehghankelishadi, Pouya, et al.
Publicado: (2023)

Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRI(ca)Col1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib)
por: Wermuth, Peter J., et al.
Publicado: (2018)

Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects
por: Ault, Patricia S., et al.
Publicado: (2016)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
por: Kreutzman, Anna, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f79dodburcm9nfam1i46cef6io